Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.

It discloses a dexamethasone-loaded macrophage-derived microvesicle as well as a preparation method and application thereof. The dexamethasone-loaded macrophage-derived microvesicle is formed by entrapping dexamethasone with a microvesicle derived from a murine macrophage cell line 264.7 cell. The dexamethasone-loaded macrophage-derived microvesicle of the present invention can be taken up by an injured cell more effectively, and fulfills the aim of ameliorating the kidney inflammation by inhibiting the activation of a proinflammatory signal pathway and infiltration of inflammatory cells. Meanwhile, the preparation method of the present invention is simple, convenient and efficient, and the prepared microvesicle is derived from the RAW 264.7 cells which are sufficient and widespread, and can be produced in large-scale.

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Provided herein are methods for preparing liposomes comprising increased concentration of hydrophobic therapeutic agents and improved stability, and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts.

Disclosed herein are liposomal pharmaceutical compositions encapsulating one or more anticancer agents and methods of using the liposomal pharmaceutical compositions for treating cancers, in which multiple anticancer agents can be administered to a cancer patient in a synergistic molar ratio through liposome delivery particles. Methods of preparing the liposomes encapsulating multiple anticancer agents and the pharmaceutical compositions thereof are also disclosed.

The present invention discloses a liposome formulation, its preparation method, and its application in the treatment of diseases caused by abnormal gene expression. The liposome formulation comprises complementary cationic lipid pairs, phospholipids, and long-circulating lipids. The method of preparing the liposome formulation comprises: mixing the complementary cationic lipid pairs with the phospholipid and the long-circulating lipid to generate pre-formed vesicles; and then mixing the pre-formed vesicles with the nucleic acid solution to generate the liposome-nucleic acid formulation. This liposome formulation provided by the present invention is easily prepared; and in the treatment of diseases caused by abnormal gene expression, the liposome formulation can be used to deliver in vivo therapeutic agents, including nucleic acids.

Improved methods for efficiently constituting liposome encapsulated vincristine for intravenous injection (VSLI) with reduced risk of operational errors and contamination are disclosed.

The present invention relates to a pharmaceutical composition comprising at least one liposome, a trapping agent and a sedative drug with a high drug to lipid ratio and a high encapsulation efficiency. Also provided are the methods to sedate or treat pain in a subject in need thereof by administering the pharmaceutical composition disclosed herein.

The present invention provides a pharmaceutical composition for subcutaneous administration comprising a blood factor and a colloidal particle comprising about 0.5 to 20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer, wherein the blood factor is not encapsulated in said colloidal particle.

Therapeutic compositions are disclosed which contain a therapeutic agent and a bile acid or bile acid conjugate. The compositions can be absorbed via enterohepatic circulation. The compositions include a cationic moiety and an anionic polymer, which are coupled through electrostatic interactions. The therapeutic compositions can be used for the treatment of diseases or disorders.